Multidrug pain management package
AssigneeAlgia Pharma, LLC
InventorsDavid L. Steinberg, Joseph Loskove, Hannah Thompson
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a multidrug pain management package to dispense two or more medicaments to treat pain comprising a primary n-polygon, and one or more concentric m-polygons, wherein each side of the n-polygon and m-polygons have at least n or m-medicament chambers capable of holding the two or more medicaments. Also disclosed herein is a multidrug pain management package comprising a disk, wherein the disk is divided into equally spaced regions, and wherein each region has chambers capable of holding medicaments. Also disclosed herein are single formulations to treat pain.
Claims40
The single formulation of claim 29, wherein the formulation is dispensed in a package to dispense two or more medicaments to treat pain, the package comprising:
- a. a primary n-polygon shaped blister layer, wherein each side of the n-polygon has at least n-medicament chambers capable of holding the two or more medicaments, and wherein the n-medicament chambers each comprise:
- a blister layer forming a sealed chamber capable of holding the two or more medicaments, wherein the two or more medicaments are between the blister layer and the chamber holding the two or more medicaments;
- and
- b. one or more concentric m-polygons within the primary n-polygon wherein the first m-polygon has n-1 or fewer sides;
- wherein each additional, optional concentric m-polygon has m-1 or fewer sides from the previous concentric m-polygon, wherein each side of the m-polygon has at least m-medicament chambers capable of holding the two or more medicaments.
5-6. (canceled)
8-10. (canceled)
13-15. (canceled)
17-21. (canceled)
The method of claim 40, wherein the single formulation is administered by the patient to manage pain post-discharge by a physician.
The method of claim 40, wherein the single formulation is administered to the patient to manage pain post-discharge by a physician.
-28. (canceled)
A single formulation consisting of comprising:
- a. acetaminophen;
- b. one or more nonsteroidal anti-inflammatory drug;
- c. a gabapentinoid;
- and
- d. at least two additional active ingredients selected from the group consisting of:
- alpha 2 agonists, corticosteroids, H2 blockers, proton pump inhibitors, antacids, SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), muscle relaxants, sleep aids drugs, natural sleep aids, magnesium, zinc, vitamin C, vitamin D, and tramadol,
- wherein the single formulation is opioid free.
-34. (canceled)
(canceled)
44-47. (canceled)
50-52. (canceled)
55-66. (canceled)
A single formulation consisting of:
- a. acetaminophen;
- b. one or more nonsteroidal anti-inflammatory drug;
- c. a gabapentinoid;
- and
- d. at least two additional active ingredients selected from the group consisting of:
- alpha 2 agonists, corticosteroids, H2 blockers, proton pump inhibitors, antacids, SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), muscle relaxants, sleep aids drugs, natural sleep aids, magnesium, and tramadol, zinc, vitamin C, vitamin D, and tramadol,
- wherein the single formulation is opioid free, and
- wherein the single formulation is given to a patient on the first day every eight hours.
A single formulation consisting of:
- a. acetaminophen;
- b. one or more nonsteroidal anti-inflammatory drug;
- c. a gabapentinoid;
- and
- d. at least two additional active ingredients selected from the group consisting of:
- alpha 2 agonists, corticosteroids, H2 blockers, proton pump inhibitors, antacids, SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin Norepinephrine Reuptake Inhibitors), (Tricyclic Antidepressants), muscle relaxants, sleep aids drugs, natural sleep aids, magnesium, zinc, vitamin C, vitamin D, and tramadol,
- wherein the single formulation is opioid free, and
- wherein the single formulation is dispensed by an inhaler to a patient.
Dependencies are inferred from the claim text.